Closure IDE
This article was originally published in The Gray Sheet
Executive Summary
Firm to begin 150-patient randomized pivotal study for vascular sealant product following FDA go-ahead, announced March 18. The 14-site U.S. and European study will evaluate the sealant's prevention of vascular leakage in patients undergoing femoral-popliteal bypass or AV-access grafting. The study features four- and 12-week follow-up under the guidance of principal investigator Alan Lumsden, MD, Baylor College of Medicine. Closure expects to conclude the study in late 2004, with CE mark approval and PMA filing slated for 2005 (1"The Gray Sheet" Feb. 23, 2004, p. 17)...
You may also be interested in...
Closure Medical Vascular Sealant Will Challenge Baxter, CryoLife Products
Closure Medical plans to focus 2004 R&D efforts on preparing and completing a definitive clinical trial for a vascular sealant device that the firm will promote as a stronger, easier-to-use alternative to Baxter's Tisseel and CryoLife's BioGlue
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.